Teprotumumab shows promise in treating dysthyroid optic neuropathy

Teprotumumab has demonstrated significant effectiveness in treating dysthyroid optic neuropathy (DON) in patients with active thyroid eye disease (TED), according to a study. The study, which reviewed 10 observational studies and case reports, supplemented by 2 cases from the authors' clinical practice, found that teprotumumab led to substantial improvements in...